Subscribe
shutterstock_1770737918_rafapress
rafapress / Shutterstock.com
17 June 2021Big PharmaAlex Baldwin

Bio-Rad asks for review of DNA patent ruling

Bio-Rad has asked the US Court of Appeals for the Federal Circuit to review its prior decisions that affirmed Bio-Rad had infringed three 10X Genomics patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Bio-Rad and 10X Genomics end patent fight with new licensing deal
29 July 2021   Bio-Rad Laboratories has settled its long-running dispute with 10X Genomics over patents covering genetic analysis tech and both companies have negotiated an agreement to cross-license their products.
Americas
10x Genomics strikes back in Bio-Rad saga with USITC ban
13 February 2020   US biotechnology company 10x Genomics has won an import ban against its rival Bio-Rad Laboratories in a long-running patent dispute.
Americas
Bio-Rad wins injunction against 10X Genomics
26 July 2019   Bio-Rad, a developer of clinical diagnostic products, secured a permanent injunction against a competitor earlier this week in a long-running dispute.


Editor's picks

In-house with Bayer: ‘Focus on quality early and stay close to inventors’
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025

Editor's picks

Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025

More on this story

Biotechnology
Bio-Rad and 10X Genomics end patent fight with new licensing deal
29 July 2021   Bio-Rad Laboratories has settled its long-running dispute with 10X Genomics over patents covering genetic analysis tech and both companies have negotiated an agreement to cross-license their products.
Americas
10x Genomics strikes back in Bio-Rad saga with USITC ban
13 February 2020   US biotechnology company 10x Genomics has won an import ban against its rival Bio-Rad Laboratories in a long-running patent dispute.
Americas
Bio-Rad wins injunction against 10X Genomics
26 July 2019   Bio-Rad, a developer of clinical diagnostic products, secured a permanent injunction against a competitor earlier this week in a long-running dispute.

More on this story

Biotechnology
Bio-Rad and 10X Genomics end patent fight with new licensing deal
29 July 2021   Bio-Rad Laboratories has settled its long-running dispute with 10X Genomics over patents covering genetic analysis tech and both companies have negotiated an agreement to cross-license their products.
Americas
10x Genomics strikes back in Bio-Rad saga with USITC ban
13 February 2020   US biotechnology company 10x Genomics has won an import ban against its rival Bio-Rad Laboratories in a long-running patent dispute.
Americas
Bio-Rad wins injunction against 10X Genomics
26 July 2019   Bio-Rad, a developer of clinical diagnostic products, secured a permanent injunction against a competitor earlier this week in a long-running dispute.

More features

AbbVie blocks Humira antitrust suit
WATCH: Enabling success—mastering s112 in the new era of life sciences patents
AstraZeneca suffers defeat over $7bn diabetes patent
US firm Brownstein nabs five from Crowell ‘at pivotal moment’
American Regent secures rare PI win in Hatch-Waxman dispute
WATCH: Patents s101—how to overcome the current complexity of patent eligibility in the US
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
J&J sues over schizophrenia drug generic following patent victory